Latest news
Evotec, Odyssey Launch R&D Partnership in Autoimmune, Inflammatory Diseases - Contract PharmaContract Pharma · Thu, 06 Aug 2026 19:16:38 GMTNiagen Bioscience price target lowered to $10 from $12 at Roth Capital - TipRanksTipRanks · Wed, 05 Aug 2026 13:08:18 GMTNiagen Bioscience advances NB4168 with Evotec support on preclinical strategy - Traders UnionTraders Union · Tue, 04 Aug 2026 18:10:12 GMTEvotec to support Niagen Bioscience in NB4168 development as contract research organization - Traders UnionTraders Union · Tue, 04 Aug 2026 05:47:40 GMTNiagen Selects Evotec to Advance Preclinical Development of Oral Small-Molecule Candidate - Contract PharmaContract Pharma · Mon, 03 Aug 2026 21:00:00 GMTNiagen Bioscience selects Evotec to advance development for NB4168 - TipRanksTipRanks · Mon, 03 Aug 2026 15:34:47 GMTNiagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168 - Business WireBusiness Wire · Mon, 03 Aug 2026 12:32:00 GMT